Alto NeuroscienceANRO
ANRO
About: Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
Employees: 88
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
360% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 5
278% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 9
48% more call options, than puts
Call options by funds: $10.5M | Put options by funds: $7.05M
33% more capital invested
Capital invested by funds: $198M [Q2] → $264M (+$66.1M) [Q3]
30% more funds holding
Funds holding: 57 [Q2] → 74 (+17) [Q3]
15.72% more ownership
Funds ownership: 69.01% [Q2] → 84.73% (+15.72%) [Q3]
50% less funds holding in top 10
Funds holding in top 10: 4 [Q2] → 2 (-2) [Q3]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$4
14%
downside
Avg. target
$10.50
126%
upside
High target
$18
288%
upside
4 analyst ratings
3 positive
75%
1 neutral
25%
0 negative
0%
Jones Trading Justin Walsh 20% 1-year accuracy 2 / 10 met price target | 288%upside $18 | Buy Initiated | 16 Dec 2024 |
Stifel Paul Matteis 14% 1-year accuracy 2 / 14 met price target | 116%upside $10 | Buy Maintained | 13 Nov 2024 |
Wedbush Laura Chico 25% 1-year accuracy 15 / 61 met price target | 14%downside $4 | Neutral Downgraded | 23 Oct 2024 |
Baird Brian Skorney 17% 1-year accuracy 4 / 24 met price target | 116%upside $10 | Outperform Maintained | 23 Oct 2024 |
Financial journalist opinion
Based on 27 articles about ANRO published over the past 30 days
Neutral
Accesswire
19 hours ago
The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud
LOS ANGELES, CA / ACCESS Newswire / January 20, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Neutral
Accesswire
1 day ago
Alto Neuroscience, Inc. Is Being Investigated For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESS Newswire / January 19, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Neutral
Accesswire
2 days ago
The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud
LOS ANGELES, CA / ACCESS Newswire / January 18, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Neutral
Accesswire
3 days ago
Alto Neuroscience, Inc. Is Being Investigated For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESS Newswire / January 17, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Neutral
Accesswire
4 days ago
The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud
LOS ANGELES, CA / ACCESS Newswire / January 16, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Neutral
Accesswire
5 days ago
Alto Neuroscience Inc Is Being Investigated For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / January 15, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Neutral
Accesswire
6 days ago
The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / January 14, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Neutral
Accesswire
1 week ago
Alto Neuroscience Inc Is Being Investigated For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / January 13, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Neutral
Accesswire
1 week ago
The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / January 12, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Neutral
Accesswire
1 week ago
Alto Neuroscience Inc Is Being Investigated For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / January 10, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Charts implemented using Lightweight Charts™